WHWK (Aadi Bio) Forward P/E Multiple
The exclusivity of its rare tumor therapy allows Aadi Bioscience Inc (WHWK) to maintain premium pricing power. The company's forward P/E ratio clearly demonstrates the market's reaction to this potential, where 0.00 reflects the current value of this metric. Well-established cold chain logistics and management's experience in bringing Fyarro to market under strict cost controls support the business's stability.
Summary analytical data breakdowns for Aadi Bio (WHWK)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Aadi Bioscience Inc|WHWK - Long-Term Liabilities to Capital|Short-Term Debt to Capital Aadi Bioscience Inc|WHWK - Company Aggregate Debts|Debts to Book Capitalization Aadi Bioscience, Inc.|WHWK - Company Long-Term Debts|Company Short-Term Debts Aadi Bioscience|Quick Ratio aadibio.com
- financial results and valuation multiples details:
WHWK - Net Financial Result|Future Profit Aadi Bioscience Inc|WHWK - Company Value to Net Income|Forward P/E Multiple Aadi Bioscience Inc|WHWK - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Aadi Bioscience, Inc.|WHWK - Operating income before deduction of amortization|Earnings per share for the last twelve months Aadi Bioscience|WHWK - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months aadibio.com|WHWK - Expected net earnings per share growth this year|Earnings growth forecast for next year Aadi Bioscience Inc
Comprehensive company analysis:Aadi Bioscience
Investors are assessing the potential of Aadi Bioscience Inc (WHWK) through the capital payback period, calculated as the ratio of the current market share price to the projected earnings per share. By analyzing the changes in the company's expected P/E ratio, one can determine to what extent the monopoly on orphan drugs and patent protection justify the current business valuation in an environment of expensive debt capital.
Analysis of competing companies
Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Forward P/E Multiple YMAB|Forward P/E Multiple aurabiosciences.com (AURA)|Forward P/E Multiple CADL (Candel Therapeutics, Inc.)|Forward P/E Multiple Accuray Inc ARAY|SELLAS Life Sciences Group Inc. - Forward P/E Multiple|ACTU (Actuate Therapeutics Inc) - Price to Future Earnings Ratio|CTOR: Forward P/E Multiple|HURA - Market Cap to Projected Earnings|Projected Price to Earnings TARA|FATE: Future Price to Earnings Multiple|Forward P/E Multiple TCRX|Future Price to Earnings CSBR (championsoncology.com)|Forward P/E Multiple XBIT (XBiotech)|Market Cap to Projected Earnings CEL-SCI Corp. (CVM)|OSTX - Future Price to Earnings|Projected Price to Earnings Ratio radiopharmtheranostics.com|artivabio.com (ARTV) - Future Price to Earnings|ANL - Market Cap to Projected Earnings|VERU (Veru Inc.) - Forward P/E Multiple|Projected Price to Earnings tempesttx.com (TPST)|Forward P/E Multiple XLO|Market Cap to Projected Earnings renovarobio.com|Forward P/E Multiple MURA (Mural Oncology)|Kairos Pharma Limited (KAPA) - Projected Price to Earnings Ratio|OKUR - Future Price to Earnings|GDTC (CytoMed Therapeutics) - Price to Future Earnings Ratio|CRIS: Forward P/E Multiple|Projected Price to Earnings Apollomics|THAR (Tharimmune Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Advanced Biomed Corp ADVB|Projected Price to Earnings GNPX (Genprex, Inc.)|CLDI (calidibio.com) - Future Price to Earnings Multiple|Forward P/E Multiple SBFM (Sunshine Biopharma, Inc.)|Market Cap to Projected Earnings Xenetic Biosciences Inc. (XBIO)|SLRX - Future Price to Earnings|PPBT (Kitov Pharma) - Price to Future Earnings Ratio|AONC: Forward P/E Multiple|Projected Price to Earnings beigene.com|Projected Price to Earnings CKPT|Projected Price to Earnings elevationoncology.com (ELEV)|Forward P/E Multiple ICAD|IKNA (ikenaoncology.com) - Future Price to Earnings Multiple|Notable Labs, Ltd. - Projected Price to Earnings|VIRX - Projected Price to Earnings|MOR - Future Price to Earnings|NAYA - Forward P/E Multiple|AAPGV: Forward P/E Multiple
